Host adaptive immune system protein

The term "Host adaptive immune system protein" refers to a broad and diverse class of proteins that mediate the acquired immune response, rather than a single therapeutic target (Janeway et al., 2017). This category includes cell surface receptors such as T-cell receptors (TCRs) and B-cell receptors (BCRs), as well as antigen-presenting molecules like Major Histocompatibility Complex (MHC) proteins (Abbas et al., 2021). It also encompasses co-stimulatory and inhibitory checkpoint molecules, such as PD-1 and CTLA-4, which regulate the intensity and duration of the immune response (Pardoll, 2012). These proteins are essential for the body's ability to recognize specific pathogens, generate a tailored response, and establish long-term immunological memory (NIH, 2023). In clinical practice, various components of the adaptive immune system are targeted to treat a wide range of conditions, including autoimmune disorders, organ transplant rejection, and various cancers (Murphy & Weaver, 2016). Because this term encompasses hundreds of distinct proteins with vastly different biological roles and molecular structures, it is considered a functional category rather than a specific, actionable drug target (UniProt, 2024). Consequently, therapeutic development usually focuses on specific members of this system, such as individual cytokines or receptors, to achieve precise clinical outcomes (StatPearls, 2023). Targeting the system as a whole is generally not feasible, as it would lead to indiscriminate immune modulation and significant safety risks (FDA, 2024).

Other names

Adaptive immune system proteinsAcquired immune system proteinsImmunological memory proteins

Drugs targeting components of the host adaptive immune system operate through diverse mechanisms, including the inhibition of T-cell activation (e.g., calcineurin inhibitors), the blockade of immune checkpoints to enhance anti-tumor activity (e.g., PD-1 inhibitors), the depletion of specific B-cell populations (e.g., anti-CD20 antibodies), and the neutralization of pro-inflammatory cytokines (e.g., TNF-alpha antagonists) (Abbas et al., 2021; FDA, 2024).